Please assess the completion status of the following clinical trial:

Trial Title: Guanfacine to Reduce Relapse Risk in Women With Alcohol Use Disorder (AUD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must meet Diagnostic and Statistical Manual of Mental Disorders-V (DSM- V) criteria for moderate to severe Alcohol Use Disorder (AUD),~* Must produce positive urine toxicology screens on admission to study~* Must demonstrate good health as verified by screening examination~* Must be able to read English and complete study evaluations~* Must be able to provide informed written and verbal consent~Exclusion Criteria:~* Meeting current use disorder for any other psychoactive substance, excluding nicotine.~* Having any other current Axis I psychiatric disorders or medical conditions requiring treatment or medication~* EKG evidence at baseline screening of any clinically significant conduction abnormalities including a Bazlett's QTc (corrected QT interval) of \>470 msec.~* Must not be on monophasic contraceptives, nursing or pregnant.

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Guanfacine XR 3mgs/daily (Type: EXPERIMENTAL): * Guanfacine XR tablet by mouth every 24 hours for 12 weeks~* 21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)~* Full dose: 3mgs/d (day 21- day 70)~* 2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)
- Placebo (for guanfacine) (Type: PLACEBO_COMPARATOR): * Guanfacine XR tablet by mouth every 24 hours for 12 weeks~* 21 day titration: 1 mg/d (day 1-7); 2mgs/d (day 7-21)~* Full dose: 3mgs/d (day 21- day 70)~* 2 week taper: 2mgs/d (day 71-77); 1mg/d (day 77-83)

Based on this trial design, predict the completion outcome and termination type (if applicable).